Nirsevimab is likely to be the first of many tools to prevent RSV in children. A maternal RSV vaccine is currently under assessmentby the TGAand Pharmaceutical Benefits Advisory Committee (PBAC). A vaccine for older Australians,Arexvy, is registered and is also being assessed by thePBAC, wit...
COVID-19 vaccines will likely not be available for everyone in the U.S. until the Oxford-AstraZeneca vaccine is approved for use in the U.S., possibly this spring. The government has not released a timetable for when the 500,000 doses it has ordered of the two-dose vaccine will be...
For example, AstraZeneca’s respiratory syncytial virus (RSV) vaccine is based on an antibody. This is a bit of an unconventional approach for vaccines but monoclonal antibodies do not require the activation of the immune system and can thus more rapidly offer direct protection against pathogens, ...
The pandemic phase of transmission will end, but to get to an endemic phase faster, we will probably need additional COVID-19 boosters that target differentvariantsand keep the virus from causing large outbreaks, experts told Live Science. Eventually, a yearly or seasonalvaccinemay be needed to ...
Mary K. Caffrey
(RSV), another respiratoryvirusthat for most of us causes cold and flu-like symptoms but that can be much more severe in infants, the elderly, and those with respiratory conditions. We don't yet have an approved vaccine or highly effective treatment for RSV. And while we have modestly ...
The only infectious disease in modern history to be eliminated worldwide wassmallpox,which the World Health Organization declared eradicated in 1980. But that was nearly 200 years after the creation of the first smallpox vaccine. Smallpox also spread relatively slowly, and people who had it devel...
, the new vaccine's core is a computer-designed nanoparticle made of different parts shaped like pentagons and triangles. Each nanoparticle is more than ten million times smaller than a poppy seed. The outsides of these nanoparticles were fitted with inert RSV proteins to create the vaccine....
Nearly three-quarters (72%) of the independent pharmacists who responded to the annualDrug Topicsbusiness outlook survey had a hunch that their business prospects in the year ahead are good to excellent. Their optimism is only slightly less than the 76% in last year's survey who thought 2003...
However, at a population level, less profound impairment of specific immune processes occurring with high prevalence may manifest as an increased incidence of infection (e.g., influenza, otitis media or the common cold) [21] and reduced vaccine effectiveness [22] (Figure 1). For vulnerable sub...